A patent for a system that gives more reliable results in gene technology-based diagnostic tests has been granted to researchers at the Norwegian Institute of Public Health (NIPH).
Gene technology analysis is used increasingly in diagnostic tests for detection of minute amounts of cells, bacteria and viruses in biological samples. However, false positive or negative results may occur.
- To uncover false negative results, an internal control reagent can be included in the tests to verify that the analysis results are valid. The problem with the internal controls used in today’s analyses is that they can only be added during, or at the end of the analysis process. This means that quality assurance is incomplete, explains Einar Sverre Berg at the Department for Virology.
Together with colleague Kjell Skaug he invented a protective shell for the internal control, based on cell/virus-mimicking liposomes. The liposome/internal control particles can thus be mixed with the biological test material when the sample is taken and be present during the entire analytical process. Whole process quality assurance is thereby achieved with more reliable results.
Chlamydia test first
Berg and Skaug were among the first in the world to show that restrictive substances in urine samples are an important source of false negative results in gene technology-based chlamydia tests.
The scientists recognised the problem with incomplete quality assurance, and invented the solution for the tests.
- A fantastic property of the system is that it isn’t limited to just one test. It can be used in any gene technology-based assay detecting biologically substances. The liposome can be tailored and adapted according to the target – be it a virus or bacterium. The potential, in other words, is enormous, says Berg.
Berg and his colleague have applied for a patent on their discovery in all industrialised countries and have established the company IC Particles AS. Patents were first granted in New Zealand and Australia, followed by Norway. Berg is also optimistic about getting a patent in the USA within this year.
- Without the NIPH’s goodwill and patience it is likely that the IC Particle’s invention would not have been developed, concludes Einar Sverre Berg.
Source: Norwegian Institute of Public Health
Related stories:
Political participation is partially rooted in genetic inheritance
The decision to vote is partly genetic, according to a new study published in the American Political Science Review. The research, by James H. Fowler and Christopher T. Dawes, of the University of California, San Diego and Laura A. Baker, of the University of Southern California, is the first to show that genes influence participation in elections and in a wide range of political activities.
New electrostatic-based DNA microarray technique could revolutionize medical diagnostics
The dream of personalized medicine — in which diagnostics, risk predictions and treatment decisions are based on a patient's genetic profile — may be on the verge of being expanded beyond the wealthiest of nations with state-of-the-art clinics.
Automated microfluidic device reduces time to screen small organisms for genetic studies
Genetic studies on small organisms such as worms and flies can now be done more quickly using a new microfluidic device developed by engineers at the Georgia Institute of Technology.
Known Genetic Risk Alzheimer's In Whites Also Places Blacks At Risk
A commonly recognized gene that places one at risk for Alzheimer’s disease does not discriminate between blacks and whites, according to new research led by Florida State University.
Same drug, different results: MUHC researcher on the path to personalized medicine
Minor genetic differences between individuals change the effect of a common medication, study shows
Medicine has moved a little bit closer to the era of tailor-made treatments, based on the unique genetic profiles of individual patients, according to recent research conducted by Dr Rima Rozen of the Research Institute of the McGill University Health Centre (RI MUHC) at the Montreal Children's Hospital and McGill University. Her study, published June 18 in the journal Pharmacogenetics and Genomics, shows how minor genetic differences between individuals alter the way a common drug affects the body.
Known genetic risk for Alzheimer's in whites also places blacks at risk
A commonly recognized gene that places one at risk for Alzheimer's disease does not discriminate between blacks and whites, according to new research led by Florida State University.
Inherited melanoma risk: What you do know does help you
When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively—much like those who have already been diagnosed with the potentially deadly disease, according to results of a study completed at the University of Utah's Huntsman Cancer Institute. and published in the June issue of
Cancer Epidemiology, Biomarkers & Prevention.
Statistical tool could explain gene study variations
While scientists are using the human genome to associate certain genes with disease, Dr. Hongyan Xu wants to ensure they are accounting for natural variations in those genes.